ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Marinus Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – MRNS

Group 1 - The Rosen Law Firm is reminding investors who purchased Marinus Pharmaceuticals, Inc. securities between March 17, 2021, and May 7, 2024, of the August 5, 2024, lead plaintiff deadline in the securities class action [4][8] - Investors may be entitled to compensation without any out-of-pocket fees or costs through a contingency fee arrangement [2] - The lawsuit alleges that defendants made materially false and misleading statements regarding the risks associated with the RAISE trial and its implications for the company's operations [8] Group 2 - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [5] - The firm has been recognized for its success in securities class action settlements, being ranked No. 1 by ISS Securities Class Action Services in 2017 and consistently in the top 4 since 2013 [5] - Investors have the option to select their counsel or remain absent as class members, as no class has been certified yet [6]